Global Initiatives

Antibiotic Action is working collaboratively with a number of likewise initiatives across the globe.  Below you can find details of other international organisations and intiatives pushing the same important agenda forward.  If you know of others please let us know by contacting Michael Corley, Senior Policy and Public Affairs Officer –

The following initiatives appear in alphabetical order.


Alliance for the Prudent Use of Antibiotics

Alliance for the Prudent Use of Antibiotics The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters in over 66 developed and developing countries, we conduct research, education and advocacy programs to control antimicrobial resistance and ensure access to effective antibiotics for current and future generations.

Antibiotic Research UK

Antibiotic Research UK Antibiotic Research UK (ANTRUK) is a national charity dedicated to finding new antibiotics against resistance bacteria. It aims to raise money primiarily in the UK and is seeking support from Foundations, Trusts, Industry, and the general public. The Charity is a Charitable Incorporation Organisation (CIO) and is able to act as a not for profit company.

BEAM Alliance

BEAM Alliance (Biotechs from Europe innovating in anti-microbial resistance) is a group of European small medium enterprises (SMEs) that are committed to improving the regulatory, investment, and commercial environments in Europe for research, development, approval, and market viability of new products that combat antimicrobial resistance.


CARB-X, or the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, is investing in drug and diagnostic discovery and development projects to tackle antibiotic resistance. The group will help biotech companies and research teams to accelerate the development of new life-saving antibacterials and diagnostics aimed at treating infections caused by the world’s deadliest antibiotic-resistant bacteria.

Chennai Declaration

Chennai Declaration A joint meeting of medical societies in India was organized as a pre-conference symposium of the 2 nd annual conference of the Clinical Infectious Disease Society (CIDSCON 2012) at  Chennai on 24 thAugust 2012.  This landmark event examined how medical societies in India can work together to tackle the issue of resistance working collaboratively to formulate a road map to tackle the global challenge of antimicrobial resistance from the Indian perspective.

Global Antibiotic Resistance Partnership (GARP)

Global Antibiotic Resistance Partnership (GARP) The Global Antibiotic Resistance Partnership (GARP) develops actionable policy proposals on antibiotic resistance for low- and middle-income countries.  Proposals identify weaknesses in how antibiotics are developed, regulated, and managed, and how well countries track antibiotic use and resistance.   Phase 1 of GARP encompassed work in four countries: India, Kenya, South Africa, and Vietnam.  The expertise and capacity developed in these initial four countries is the core of a wider partnership involving other low- and middle-income countries to create greater awareness among national policymakers about the need for policies to control antibiotic resistance as part of a worldwide effort.


ReAct – Action on Antibiotics ReAct is an independent global network for concerted action on antibiotic resistance.  ReAct aims for profound change in awareness and action to manage the interacting social, political, ecological and technical forces that drive the rising rate of resistant human and animal infection and the rapid spread of resistance within and between communities and countries.


Transatlantic task force on urgent antimicrobial resistance – TATFAR The EU-US Summit Declaration agreed on 3 November 2009 called for the establishment of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us”. The objectives of the task force are to increase the mutual understanding of US and EU activities and programmes relevant to the antimicrobial resistance issues, identified in the declaration, to deepen the transatlantic dialogue, to provide opportunities to learn from each other, and to promote information exchange, coordination and co-operation. The outcomes of the task force will include a proposal with suggestions for areas of future cooperation between the EU and the US to be presented at the EU-US Summit in 2011.

World Alliance Against Antibiotic Resistance

World Alliance Against Antibiotic Resistance ( WAAR) The World Alliance Against Antibiotic Resistance (WAAR) comprises health care professionals, consumers, health managers, and politicians. The alliance has developed a statement that represents a strong consensus between the different professionals, including general practitioners, and veterinarians on a series of actions and measures to tackle antibiotic resistance. The alliance is coordinated by Jean  Carlet  (past president of the French CTIN, WHO consultant for the  African Partnership  for Patients Safety (APPS) project

World Health Organisation

The World Health Organisation is the directing and coordinating authority on international health within the United Nations’ system.

It does this by:

  • Providing leadership on matters critical to health and engaging in partnerships where joint action is needed;
  • Shaping the research agenda and stimulating the generation, translation and dissemination of valuable knowledge;
  • Setting norms and standards and promoting and monitoring their implementation;
  • Articulating ethical and evidence-based policy options;
  • Providing technical support, catalysing change, and building sustainable institutional capacity; and
  • Monitoring the health situation and assessing health trends.